MDMA Treatment

PharmAla's Novel MDMA Mixture Awarded US Patent, Enabling IP Protection And Further Development
Psyched: Psychedelics & Sex, MDMA And Federal Approval, Canadians For End-Of-Life Care And More
Psychedelics Headlines: Magic Mushrooms For Sexual Wellbeing, The DEA's Stance, The Therapist's Role & More
Psyched: Psychedelics & Sex, MDMA And Federal Approval, Canadians For End-Of-Life Care And More
Psychedelics Headlines: Magic Mushrooms For Sexual Wellbeing, The DEA's Stance, The Therapist's Role & More
Incannex Healthcare To Open First Psychedelic-Assisted Therapy Clinic In Australia
Psyched: Biden's Big Decision On Psychedelics Therapy; LSD Anxiety Results; Matthew Perry Autopsy And More

MDMA Treatment Recent News

MindMed Q3 2023: Financials, Business Funded By 2026 If LSD Pipeline Milestones Achieved
Clinical-stage psychedelics biotech Mind Medicine (MindMed) (NASDAQ: MNMD) has shared its financial outcomes for the third quarter ended September 30, 2023. In numbers:
PharmAla Files IP Protection For Novel MDXX Molecule: Viability As Autism Spectrum Treatment
Canadian biotech company PharmAla Biotech Holdings (OTC: PMBHF) has filed a patent covering composition of matter of Novel Chemical Entity (NCE) PharmAla-1. 
Hollywood's Psychedelics Craze, Is Drew Barrymore Joining The Trend?
Former child star and one of the beloved Charlie’s Angels, Drew Barrymore hinted that she would consider MDMA or psilocybin therapy “as a way to get to some state where I could see things in a different way.” As hostess of The Drew Barrymore Show, she encourages guests to open up emotionally. 
Terran Biosciences Seals Deal With France's Pierre Fabre Pharmaceutical
New York-based biotech Terran Biosciences has signed an agreement with French pharmaceutical company Pierre Fabre Médicament for worldwide exclusive rights to develop and commercialize a list of the latter's assets targeting neuropsychiatric conditions.
EXCLUSIVE: AMA Moves Toward Psychedelic Therapy Reimbursement, Filing A Gap In Regulations
The American Medical Association (AMA) is expected to issue the first code for psychedelic therapy reimbursement, following the approval of a joint application submitted by MAPS PBC and COMPASS Pathways (NASDAQ: CMPS).
New Set Of MDMA Analogs To Hit The Clinic: These Are The Latest Positive Findings
Psychedelics biotech Mydecine Innovations Group (OTC: MYCOF) is advancing the development of its novel compounds family of next-gen MDMA analogs. So far, Mydecine's compounds show promising pharmacokinetics (PK) and pharmacodynamics (PD) in preclinical models. 
Bipartisan Letter Calls For Including Active Service Members In Psychedelic-Assisted Therapy Research
A bipartisan legislative effort led by Rep. Dan Crenshaw aims to urge the participation of active-duty servicemembers in the National Institutes of Health (NIH)-funded research with psychedelics.
MindMed Reports Full-Year 2022 Financial Results, Highlighting Anxiety & Autism Studies
Clinical-stage biopharma company Mind Medicine (MindMed), Inc. (NASDAQ: MNMD) shared its financial results for the full year ended Dec. 31, 2022. Numbers show solid stability:
Australia Receives First Batch Of Clinical-Grade Psilocybin From Mindset Pharma And PharmAla
The exclusive sales partnership between psychedelics biotechs Mindset Pharma (OTCQB: MSSTF) and PharmAla Holdings resulted in the first sale of Mindset’s GMP-compliant psilocybin in Australia.
Psyched: 12 States Discuss Legalization Bills, Ceremonies For Veterans With TBI, Ketamine And MDMA Fast-Tracks & More
Psychedelics Legislation: The Latest On Hawaii, Virginia, Missouri & More
These Two Psychedelics Companies Team Up In An Exclusive Sales Deal, Here Are The Details
Next-gen psychedelics producers Mindset Pharma Inc. (OTCQB: MSSTF) and PharmAla Biotech Holdings Inc.
Clinical Research Comparing Effects Of Novel MDMA Matches In Healthy Patients Begins In Switzerland
The clinical trial investigating the effects of MDMA analogs in healthy volunteers led by PI Prof. Dr. Matthias Liechti and supported by psychedelics biotech company Mind Medicine Inc. (NASDAQ: MNMD) has begun patient dosing. 
MindMed Reveals Results Of A Study On Personalized MDMA Dosing
Psychedelic medicine biotech company MindMed (NEO: MMED) (OTCQB: MMEDF) (DE: MMQ) reported Monday the results of a study on MDMA dosing optimization utilizing perso

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga

© 2024 Benzinga | All Rights Reserved